Bayer: Beyonttra approved by the EU in ATTR-CM

(CercleFinance.com) - Bayer announced on Tuesday that the European Commission had granted marketing authorization for Beyonttra (acoramidis) in the treatment of transthyretin cardiac amyloidosis (ATTR-CM).


In a press release, the German pharmaceutical group states that it plans to start marketing Beyonttra in Europe during the first half of the year.

Acoramidis, developed by BridgeBio Pharma, had already been approved by the US Food and Drug Administration (FDA) last November.

While BridgeBio holds the marketing rights for the US, Bayer has acquired exclusive rights for Europe.

Amyloid transthyretin cardiomyopathy (ATTR-CM) is a rare, under-diagnosed and potentially life-threatening disease.

Copyright (c) 2025 CercleFinance.com. All rights reserved.